CTOs on the Move


 
We are a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Our proprietary insulin formulations are designed to be more rapid-acting than the formulations currently available to Type 1 and Type 2 diabetes patients. We refer to these as "ultra-rapid-acting" formulations. Our glucagon formulations and presentations are designed to be stable at room temperature and are intended for use by caregivers with ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.biodel.com
  • 100 Saw Mill Rd
    Danbury, CT USA 06810
  • Phone: 203.796.5000

Executives

Name Title Contact Details

Similar Companies

Sovereign Pharmaceuticals

Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.

Northeast Process Systems

Northeast Process Systems is a Gloucester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azur Pharma

Azur Pharma is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareFirst Urgent Care

Quality medical attention and care when you need it. All locations offer PCR, Rapid, Antinbody, and Rapid Antibody testing. Open 8am to 8pm, 7 days a week!

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.